Pharmacy Times®
Specialty Pharmacy Times
  • Specialty Drugs: Year in Review 2014
  • Are the Political Winds Shifting for Medical Marijuana?
  • The New Paradigm in Specialty: Payer Formulary Control?
  • Managing Care and Costs for Orphan Conditions
  • CMS Under Increased Pressure to Make Accurate Payments for Prescription Drugs
  • Why a Holistic, Technology-Enabled Treatment Approach Is Necessary to Address Hepatitis C–Related Liver Disease
Anti-Androgen Drugs May Benefit Triple-Negative Breast Cancer Patients
Davy James, Associate Editor
Study reveals optimistic findings for patients without other options for targeted cancer therapy.
Investigational HIV Treatment Shows Promise in Mid-Stage Study
Ryan Marotta, Assistant Editor
Study finds that that 61 to 82% of patients treated with experimental achieved undetectable viral replication levels.
Testicular Cancer Patients More Likely to Develop Prostate Cancer
Davy James, Associate Editor
Men who had testicular cancer also more likely to develop higher risk prostate cancers.
Viekira Pak by AbbVie Inc
Michael R. Page, PharmD, RPh
Viekira Pak is an all-oral regimen that has been approved by the FDA for the treatment of genotype 1 chronic hepatitis C virus infection.
Perjeta by Genentech, Inc
Michael R. Page, PharmD, RPh
Perjeta (pertuzumab) is now approved for the neoadjuvant treatment of breast cancer.
Featured Video
The Challenge of Getting Specialty Drugs from Manufacturer to Patient
Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses how to overcome the hurdles that hinder patient access to specialty medications.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Conference Calendar
â—„        February 2015        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2015
Intellisphere, LLC. All Rights Reserved.